Preliminary studies have suggested that -aminobutyric acid type A (GABA A ) receptors, and potentially the GABA A 5 subtype, are deficient in autism spectrum disorder (ASD). However, prior studies have been confounded by the effects of medications, and these studies did not compare findings across different species. We measured both total GABA A and GABA A 5 receptor availability in two positron emission tomography imaging studies. We used the tracer [ All participants were free of medications. We also performed autoradiography, using the same tracers, in three mouse models of ASD: the Cntnap2 knockout mouse, the Shank3 knockout mouse, and mice carrying a 16p11.2 deletion. We found no differences in GABA A receptor or GABA A 5 subunit availability in any brain region of adults with ASD compared to those without ASD. There were no differences in GABA A receptor or GABA A 5 subunit availability in any of the three mouse models. However, adults with ASD did display altered performance on a GABA-sensitive perceptual task. Our data suggest that GABA A receptor availability may be normal in adults with ASD, although GABA signaling may be functionally impaired.
INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by impairments in social communication and interaction, together with restricted and repetitive behaviors and interests (1-3). The prevalence of ASD is estimated at 0.6 to 1.5%, with each case of the disorder being associated with projected lifetime care and loss of productivity costs of around $1.5 million (4, 5) . Currently, there are no specific "disease-modifying" pharmacological treatments for ASD, and drug discovery has been hampered by poor understanding of the pathophysiology of the condition.
There is, however, increasing evidence for an excess of the brain excitatory neurotransmitter glutamate as well as a deficit in inhibitory -aminobutyric acid (GABA) in ASD (6) (7) (8) . For instance, reduced expression of the enzyme that synthesizes GABA, glutamic acid decarboxylase, has been observed in postmortem ASD brain tissue (9) . In vivo, alterations in glutamate and glutamine have been reported in the cortex and basal ganglia of children and in the basal ganglia of adults with ASD, as measured by [ (14, 15) . However, a limitation of [ 1 H]MRS imaging is that it is unable to determine neurotransmitter receptor density.
Alterations in the expression of GABA receptors, of which GABA type A (GABA A ) is the most prevalent type in the brain (16) (17) (18) , may be a key contributor to the excitatory/inhibitory imbalance in ASD. Reductions in the density of GABA A receptors have been reported in the hippocampus (19) and cingulate cortex (20, 21) of postmortem brain tissue from people with ASD. Although these studies were valuable first steps, their sample sizes were small, and they included individuals taking medications such as anticonvulsants that might alter GABA A expression, leaving it unclear whether their findings could be replicated by in vivo studies.
Two in vivo studies have reported reductions of GABA A in ASD. Using [ 123 I]iomazenil single-photon emission computed tomography (SPECT), Mori et al. (22) reported decreased GABA A availability in children with ASD. However, this study included children with epilepsy and intellectual disability, and some participants were on anticonvulsant drugs. Hence, it remained unclear whether it was ASD, or a confounding factor, that was associated with reduced GABA A receptor availability. Therefore, we subsequently carried out a pilot study (23) using positron emission tomography (PET) with the tracer [ Hence, we designed the present investigation to replicate and extend prior in vivo GABA A imaging studies in a new and larger participant sample; the data from the pilot study were not included in the present analysis.
We reasoned that if the GABA A receptor availability was abnormal in ASD, it might provide a useful therapeutic target for drug development. To provide a rational screen for new treatments, however, drug development would require animal models that recapitulate any GABA A receptor alterations observed in humans. Therefore, we set out to examine whether GABA A receptor alterations were present in animal models of nonsyndromic ASD as well as in individuals with nonsyndromic ASD. Altered GABA A receptor expression has been reported in rodent models of ASD associated with syndromic disorders including Fragile X syndrome (24) and Rett syndrome (25, 26) . However, about 90% of ASD cases (and all of the cases in the present study) were nonsyndromic (27) , thus necessitating that we used nonsyndromic rodent models of ASD.
A final motivation for this study was to investigate GABAergic function in adults with ASD. This was based on our reasoning that the functional integrity of GABAergic circuits might be abnormal in ASD even if GABA A receptor availability was unchanged. Our aims in the present investigation were (i) to confirm whether GABA A receptor density was altered in individuals with nonsyndromic ASD compared to control individuals without ASD; (ii) to determine whether any putative changes were specific to the GABA A 5 subunit; (iii) to discover which, if any, of the three rodent models of nonsyndromic ASD displayed the same pattern of GABA A receptor alterations as potentially observed in individuals with ASD; and (iv) to determine whether ASD was associated with functional impairments in GABAergic circuits using a proxy measure of GABAergic function in individuals with ASD.
We therefore conducted an imaging study of GABA A receptor availability in both adults with ASD and three rodent models of ASD. In humans, we carried out two PET imaging studies in two independent clinical centers: in Stockholm, Sweden using [ (29, 30) . We chose [ 11 C]flumazenil as a nonselective tracer because it binds to 1, 2, 3, and 5 subunits of the GABA A receptor (31) and thus has approximately equal affinity for most of GABA A receptors in the brain (32) . The tracer [ 11 C]Ro15-4513 was chosen for its 10-fold higher affinity for the 5 subunit over the other subunits 1 to 4 and 6, for which it has approximately equal affinity (31) . The 5 subunit of the GABA A receptor has been linked to ASD (23, 33, 34) . Both PET imaging studies formed part of the Innovative Medicines Initiative (IMI) European Autism Interventions Multicenter Study (EU-AIMS) and it's successor AIMS-2-TRIALS (tables S1 and S2) (35) .
We selected three commonly used, etiologically diverse, rodent models of ASD that represent a range of genetic risk factors for ASD in humans: mice lacking Cntnap2 (36), mice lacking Shank3 (37), and mice carrying a genetic deletion equivalent to deletion of human C]Ro15-4513 tracer showed GABA A receptor availability in the human brain (n = 12 ASD adults and n = 16 control adults). BP ND was calculated using stationary wavelet-aided parametric imaging. V T was calculated using the Logan method. chromosome 16p11.2, one of the most common copy-number variants found in ASD (38) . Using the same radiotracers that we used for our PET imaging studies, we performed autoradiography to quantify GABA A receptors in the mouse brain. Autoradiography was used rather than small-animal PET imaging because it provides better spatial resolution and because PET imaging would have required the animals to be anesthetized during imaging, which could affect GABA receptor availability. Finally, to investigate the functional balance between excitatory and inhibitory neurotransmission using a visual psychophysics task, we used the paradoxical motion perception (PMP) task known to be a proxy measure of GABA function in individuals with and without ASD (39, 40) . There were no correlations between GABA A receptor availability in the gray matter of the brains of adults with ASD or control non-ASD subjects and performance on this battery of ASD-related cognitive and social cognitive tasks (table S7). The performance of the ASD group was significantly lower than the control group on letter fluency (t = −3.27, P = 0.006) and alterations between categories (t = −3.96, P = 0.001). In social cognitive tests, the ASD group performed significantly lower on all tasks: Reading the Mind in the Eyes (t = −3.96, P = 0.001), identifying the number of situations in the MASC test (t = −4.74, P < 0.001), and Faux Pas Test (t = −3.89, P = 0.002). No significant group differences were found in the central coherence tasks. (table   S4 ). There were no significant differences in [ 11 C]Ro15-4513 tracer dosing between the ASD and non-ASD groups (table S1) .
RESULTS

PET imaging with [
In a secondary analysis of the [ 11 C]Ro15-4513 binding data, we used nonlinear spectral analysis (23) to distinguish between GABA A receptor 5 and non-5 subunit availability. We confirmed that there were no differences in the total brain availability of either non-5 (t 24 = −0.163, P = 0.872, d = 0.064) or 5 (t 23 = −0.805, P = 0.429, d = 0.322) receptor subunits in adults with ASD versus control individuals without ASD. Across different brain areas, there were no regional differences in either non-5 or 5 receptor subunit availability in any brain area. We did observe an apparent increase in 5 receptor subunit availability in the insula of adults with ASD compared to control individuals without ASD (t 18 = −2.345, P = 0.029, d = 1.063), but this increase disappeared after Bonferroni correction for multiple comparisons (Figs. 1, 3B, and 4) . Notably, we did not observe any differences in 5 subunit availability in the hippocampus or amygdala (P > 0.3), the areas in which significant differences were detected in our previous pilot study (23) . Finally, there was no difference between adults with ASD compared with control individuals without ASD in terms of age or IQ (Table 1) .
Autoradiography in brain tissue from three ASD mouse models and WT mice shows no difference in GABA A receptor availability We performed autoradiography in vitro to detect GABA A receptor availability in brain tissue from three mouse models of ASD: mice lacking Cntnap2, mice lacking Shank3, and mice with a 16p11.2 deletion. Brain tissue from six brain regions-the frontal cortex, cingulate cortex, caudate/putamen, dorsal hippocampus, cerebellum, and amygdala-was examined bilaterally. We observed no significant differences in the specific binding of either the [
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tracer or the [ 3 H]Ro15-4513 tracer in brain tissue from any of the three mouse models compared to WT animals (all P > 0.05) (Fig. 5,  fig. S1 , and source data in table S8).
We subsequently examined the left and right amygdala separately, following Bertelsen et al. (46) , who reported an increase in binding of the Ro15-4513 tracer in the left amygdala of rats with ASD induced by valproate. We found no significant differences in either was observed (adjusted P = 0.09) in the left amygdala. In Cntnap2-deficient mice, there was a trend toward an increase in binding of A difference between adults with and without ASD in the PMP task We used the PMP task as a proxy measure of GABA signaling in the visual cortex of adults with ASD compared to control individuals without ASD. We first verified that the PMP effect (39) was present in the control individuals without ASD. The effect was significant (one-sample t test: t 17 = 3.99, P < 0.001; mean PMP ratio, 1.844; 95% confidence interval, 1.398 to 2.290, where a ratio of 1 is no effect), demonstrating successful implementation of the task (Fig. 6) .
The magnitude of the contrast-induced motion perceptual impairment ratio was reduced in the ASD group compared to the control group [independent samples t test with Welch-Satterthwaite correction for unequal variances: t 28 = 2.487, P = 0.022, d = 0.921 (two-tailed); Bootstrapped t test: P = 0.028 with 10,000 samples; Fig. 6 ]. Adults with ASD were less impaired by the high-contrast stimuli than were control individuals without ASD. This group difference was not accounted for by low-level differences in the ability to detect motion because there were no group differences in perceptual threshold under the two control conditions (both P > 0.4). Furthermore, the paradoxical effect of contrast on motion perception did not correlate with age (n = 30, r = 0.026, P = 0.892) or IQ (n = 29, r = 0.243, P = 0.203). Thus, adults with ASD showed a selective enhancement in motion perception under conditions of high contrast, results considered consistent with a defect in GABA signaling.
DISCUSSION
We conducted a PET imaging study at two different sites (London and Stockholm) to measure GABA A receptor availability in the brains of adults with ASD compared to adults without ASD. We also conducted an autoradiography study in three mouse models of ASD. Our objective was to test the hypothesis that ASD is associated with reduced amounts of GABA A receptors in the brain. We found no direct evidence in support of this hypothesis. Our results show that the unmedicated adults with idiopathic ASD but without intellectual disability in our study exhibited normal availability of both total GABA A receptors and the key GABA A receptor subunit, 5. There were no correlations between GABA A receptor availability and performance in the following social cognitive tests: Reading the Mind in the Eyes, MASC, and Faux Pas. Furthermore, we found using autoradiography that GABA A receptor availability was not altered in the brains of three mouse models of ASD: Cntnap2-deficient mice, Shank3-deficient mice, and mice with a 16p11.2 deletion. A visual perceptual proxy measure of cortical GABAergic signaling, the PMP task, revealed evidence consistent with a functional GABA signaling deficit in adults with ASD in the [ Our results contrast with reports of reduced GABA A receptor availability in children with ASD using SPECT imaging (22) . The difference between those results and our data may indicate an agespecific alteration in GABA A receptor availability in ASD, but other methodological differences should also be considered. For instance, in the SPECT imaging study, the control group consisted of patients with epilepsy, most of whom were medicated with anticonvulsant drugs. In contrast, we recruited medication-free adults with ASD and control individuals without ASD who showed typical development to avoid any medical or medication confounds. The null findings in our PET imaging study also stand in contrast to the results of our prior pilot study (23) that reported reduced GABA A 5 subunit availability in three adults with ASD compared to three matched controls. It is possible that our prior finding reflected a type I error.
Although our current results suggest that GABA A receptor availability was not altered in ASD, other interpretations of our data should be considered. One possibility is that our two studies lacked statistical power to detect any differences in GABA A receptor availability. Both of our PET imaging studies were powered at 80% to detect a typical effect size (44) . A second possible explanation for our negative result is that the PET imaging tracers we used were not sensitive enough. However, we consider this to be unlikely because both the [ We did not find any detectable differences in GABA A receptor availability using the tracers [
11 C]flumazenil and [ 11 C]Ro15-4513 and PET imaging in adults with and without ASD. We did, however, observe an alteration in performance between the two groups on a visual perception task that has been proposed as an index of cortical GABAergic function (39, 40) . A number of other groups have reported similar findings in individuals with ASD (50). This raises the possibility that the GABAergic system may be dysregulated in ASD despite an intact GABA A receptor density in the brain. For instance, it is possible that the synthesis or release of GABA is down-regulated in ASD, leading to impaired GABAergic signaling (51) . Moreover, although GABA A receptors may be present in normal numbers, they may be abnormally localized on postsynaptic neuronal membranes, thus affecting their functionality, as has been observed in epilepsy (52) . Future research studies should explore these possibilities.
Our rodent autoradiography results support our PET imaging findings in adults with ASD. GABA A receptor availability was not altered in the brains of any of the three genetic mouse models of ASD that we examined. Alterations in GABA A receptor availability might have been expected on the basis of the functions of the genes deleted in the three mouse models. Cntnap2 encodes a cell adhesion molecule belonging to the neurexin family (53) that is involved in dendritic arborization and neuronal spine development. Cntnap2 knockout mice show impaired excitatory synapse function and reduced inhibitory (GABAergic) transmission (50) . Shank3 is another synaptic protein that plays a role in signaling to presynaptic neuronal membranes through the neuroligin-neurexin trans-synaptic signaling complex (54), and Shank3 has been linked to inhibitory neuronal signaling (55, 56) . Finally, the 16p11.2 deletion is a chromosomal microdeletion associated with ASD in humans (57) . In contrast to our results, increased binding of Ro15-4513 (but not muscimol) was recently reported in the left amygdala of rats treated with valproate (46). Our current study differed from that study in a number of ways. For example, we used mice not rats, we examined genetic mouse models of ASD rather than a valproate-induced rat model of ASD, and our animals were older (12 weeks versus 7 weeks of age). Therefore, our finding of no alterations in binding of the GABA A receptor tracer in our three ASD mouse models does not rule out the possibility that other animal models might show differences in tracer binding. We suggest, however, that our data at least establish that GABA A receptor availability changes are not a shared phenotype across all animal models of ASD.
There are a number of limitations to our study. These include the fact that because of prohibitions on exposing children to research PET imaging, we were only able to recruit adults; thus, we cannot exclude the possibility that there would be abnormalities in GABA A receptor availability in children with ASD. Similarly, we were only able to recruit males in the [ 11 C]Ro15-4513 PET imaging study because of UK regulations restricting the exposure of women of reproductive age to radiation for research purposes. This limits the generalizability of our findings, although most of the individuals with ASD are males (3). Our ASD population was also free of medical comorbidities, with above average mean IQ scores and no cases of epilepsy. Although this represents a strength of the study in terms of avoidance of confounding factors, it also limits the generalizability of our findings. It is possible that GABA A receptor abnormalities are present in ASD cases who also have epilepsy or intellectual disability. Testing this hypothesis using PET imaging, however, could raise ethical issues over exposure to radiation in a vulnerable group of people who may be less able to give informed consent. Finally, we were able to selectively quantify the GABA A 5 receptor subunit, but we could not perform the same procedure for other receptor subunits such as 2 and 3 owing to a lack of suitable tracers.
A further limitation of our study is that we included only a limited range (three) of mouse genetic models of ASD for autoradiography. GABA A receptor alterations in other animal models cannot be ruled out. One could question whether the mouse models we used were appropriate models of the phenotype shown by our human ASD participants. For instance, many humans with Cntnap2, Shank3, and 16p11.2 mutations have epilepsy (58), whereas we excluded people with epilepsy in our two PET imaging studies. However, we do not think that this is a key limitation, given that we reported no differences in GABA A receptor availability in any of the three mouse models. Had we observed alterations in rodent GABA A receptor availability in mouse brain tissue, it would have been difficult to exclude the possibility that these alterations were correlates of epilepsy rather than of ASD per se; this concern does not apply to our null results. A final limitation of our PET imaging and autoradiography studies is that they were only able to quantify the density of GABA A receptors in brain tissue and not their function; other methods such as electrophysiology would be required to achieve this goal.
We used PET imaging and autoradiography to investigate the inhibitory GABAergic system in patients with ASD and in three mouse models of ASD, respectively. Our objective was to test the excitatory:inhibitory imbalance hypothesis, namely that GABA A receptor availability is reduced in ASD. Contrary to the hypothesis, we found normal availability of total GABA A receptors and the GABA A non-5 and 5 subunits in adults with ASD compared to control individuals without ASD. We recapitulated these findings in three different genetic mouse models of ASD. We did, however, find behavioral differences on the PMP task between adults with ASD and control individuals without ASD, consistent with a functional GABAergic deficit in ASD.
MATERIALS AND METHODS
Study design
We carried out two human PET imaging studies in Stockholm (Sweden) and London (United Kingdom). Each study was designed to compare GABA A receptor availability in adults with ASD to control individuals without ASD. The two studies were intended to investigate GABA A receptor availability and to provide convergent evidence from two different clinical centers. In the Stockholm study, we measured brain GABA A receptor binding using PET imaging with the nonselective tracer [
11 C]flumazenil (also known as [
11 C]Ro15-1788) (59) . In the London study, we measured GABA A receptor non-5 subunit and 5 subunit availability using PET imaging with the 5 subunit-selective tracer [ We also performed a quantitative autoradiography experiment to estimate GABA A receptor density in brain tissue from three mutant mouse strains commonly used as models of ASD: Cntnap2-deficient mice, Shank3-deficient mice, and mice with a 16p11.2 deletion (stock no. 013128, The Jackson Laboratory). Control mice included WT littermates. In all three models, there was n = 7 to 8 for the WT control mouse group and n = 8 for the mutant mouse group. Randomization was not used because this was an observational study. Analysis and quantification of images for PET and autoradiography were performed by individuals blinded to group status. In the Stockholm study, the ASD participants were recruited through the Stockholm County Health Care Services. In the London study, adults with ASD were recruited through the Behavioural Genetics Clinic at the Maudsley Hospital, a national referral service for the diagnosis of neurodevelopmental disorders. In each center, control individuals with normal development were recruited using local advertisements.
Participants and recruitment for PET imaging studies
All participants were required to meet the following criteria: (i) full-scale IQ higher than 70; (ii) not currently taking any psychoactive medications and no history of psychoactive medication use within the 6 weeks before the study; (iii) no history of epilepsy, head injury or trauma (with loss of consciousness of more than 5 min), brain disease or infection, or serious medical illness by self-report; (iv) no history of bipolar disorder, schizophrenia, drug or alcohol dependency, or other DSM (Diagnostic and Statistical Manual of Mental Disorders) Axis I disorders; (v) was physically healthy and was able to safely undergo PET imaging; (vi) not pregnant (for female participants); and (vii) aged 18 years or older.
In addition, participants in the ASD group were required to meet ICD-10 (International Statistical Classification of Diseases and Related Health Problems, 10th revision) criteria for autism and to have received a clinical diagnosis of ASD by an experienced psychiatrist involved in the study. Diagnoses were informed by the ADOS in all participants and, where possible, the ADI-R schedule (10 of 12 ASD participants in the London sample). Details on the previous use of psychoactive medications and a measure of functional impairment (employment status) are presented in table S2.
For the [ Inc./Siemens) run in three-dimensional (3D) mode with dual-energy Windows scatter correction. A 10-min transmission scan was performed to correct for attenuation and scatter. PET data were collected in a dynamic scan lasting for 63 min and binned into 26 time frames. PET images were reconstructed using filtered back projection and corrected for head motion using a frame to first frames approach. T1-weighted MR images were co-registered to PET using SPM5. MR images were segmented, and ROIs were delineated using FreeSurfer (62) . Regional BP ND values were calculated using the simplified reference tissue model, with pons acting as reference region.
[
11 C]Ro15-4513 was synthesized as previously described and injected in the dominant antecubital vein as a 15-s bolus. PET emission data were collected in 3D mode for 90 min. During the PET acquisition, arterial blood data were sampled via the radial artery using a combined automatic-manual approach. Dynamic PET data were corrected for interframe motion and aligned with the individual's structural T1-weighted MR image. An atlas was co-registered on each subject's image space, and a subset of regions including amygdala, hippocampus, and nucleus accumbens was considered. Two kinetic methods with metabolite-corrected plasma input functions were applied for the data analysis: (i) a 2TCM and (ii) a spectral-based quantification method, nonlinear spectral analysis to separate GABA non-5-and 5-related components (V 1 and V 5 , respectively) from the total tracer uptake (34) .
Autoradiography in three mouse models of ASD
We performed quantitative autoradiography to estimate GABA A receptor density in brain slices from Cntnap2 knockout (Cntnap2
) (both provided by M. Saxe, Roche), and 16p11.2 (deletion) (stock no. 013128, The Jackson Laboratory). Control mice included WT littermates. Mice were killed by decapitation, and their brains were rapidly removed and frozen in cooled isopentane. To approximate the participant demographics in the human ASD PET study as closely as possible, we used mature adult (12 weeks of age), male mice in all cases. In all three groups, there was an n = 7 to 8 for the WT mice and an n = 8 for the knockouts.
PMP task
To complement our PET imaging measures of GABA A receptor availability, we chose to investigate the functional balance between excitatory and inhibitory neurotransmission using the PMP task as a proxy measure. In this paradigm, high visual contrast normatively impairs perception of the direction of motion of sine wave grating stimuli, that is, paradoxically, lower-contrast stimuli are easier to perceive. This effect may reflect GABAergic lateral inhibition in the visual cortex (39) .
During the PMP task, participants view brief presentations of a drifting sine wave gratings of varying size (small versus large) and contrast (bright versus faint). The task is to indicate the direction of motion. PMP stimuli were grayscale vertical sine wave gratings masked with a Gaussian centered on the middle of the screen. Gratings had a spatial frequency of 1 cycle/degree of visual angle at the viewing distance of 50 cm. Each grating drifted at 2°/s either left or right (randomly determined on each trial). Stimulus size, defined as the spatial SD of the Gaussian mask, was 0.35° for small and 2.50° for large stimuli. The bright stimuli used the maximum contrast of 127 provided by the Presentation software, while the dim stimuli used a contrast of 5, which was chosen in piloting as the lowest contrast that was clearly perceptible to all participants.
There were 260 trials, 65 each of four trial types (small dim, small bright, large dim, and large bright). Psychometric estimation was performed using a 2-up-1-down duration staircase. There were four staircases, one per stimulus type. Each staircase began at 250 ms, with the step up (harder) at −14.1 ms per two correct answers (that is, the stimuli were made briefer) and step down (easier) at 18.2 ms per one incorrect answer (that is, the stimuli were made longer). A
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failure to respond was counted as incorrect. Participants performed the task in a darkened room.
In line with previous work, contrast impairment on motion perception is defined as the ratio between the estimated threshold (in milliseconds) for large-bright compared to large-faint stimuli. Trialby-trial results were analyzed using a custom Microsoft Excel macro to detect reversals. We calculated perceptual thresholds for each stimulus condition by taking the mean of all of the reversals because this is the best estimator of the psychometric threshold in a forcedchoice staircase design.
Statistics
For all analyses,  was set at 0.05, and two-tailed tests were used. For the [ 11 C]flumazenil and [ 11 C]Ro15-4513 PET imaging studies, group differences in estimated receptor availability (BP ND and V T , respectively) were compared using an independent samples t test for each of the brain regions. Results are reported as uncorrected P values, with remarks indicating whether significant results would survive Bonferroni correction over the number of brain regions within each study. For the PMP task, the magnitude of the contrast-induced motion perceptual impairment ratio was compared between groups using an independent samples t test with Welch-Satterthwaite correction for unequal variances. For the rodent autoradiography studies, nonspecific binding was subtracted from the total binding to give the specific binding values, which were compared between WT and mutant mice using unpaired t tests corrected for multiple comparisons using Šidák correction.
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